Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | LPL | P06858 | 1/20 | 0.52 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.52 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.45 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.45 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 3/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13284207 | 0.98 | MGLL (0.57) | MGLLCA2CA1LPLLIPG | |
| SCHEMBL13284206 | 0.98 | MGLL (0.57) | MGLLCA2CA1LPLLIPG | |
| SCHEMBL17899782 | 0.86 | MGLL (0.67) | MGLLCA2LPLLIPGACHE | |
| SCHEMBL6561397 | 0.82 | ACHE (0.61) | HSD17B1HSD17B2ENPP3ACHEPGR | |
| SCHEMBL21340491 | 0.82 | HSD17B2 (0.41) | MGLLCA2CA1HSD17B1HSD17B2 | |
| SCHEMBL12419993 | 0.81 | CA1 (0.82) | MGLLCA2CA1HSD17B1HSD17B2 | |
| SCHEMBL2846622 | 0.81 | MGLL (0.79) | MGLLCA2CA1HSD17B1HSD17B2 | |
| SCHEMBL20955808 | 0.81 | CA1 (0.82) | MGLLCA2CA1HSD17B1HSD17B2 | |
| SCHEMBL30445177 | 0.81 | CA1 (0.82) | MGLLCA2CA1HSD17B1HSD17B2 | |
| SCHEMBL17003467 | 0.81 | CA2 (0.58) | MGLLCA2CA1LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3405192-B1 | BRUTON'S TYROSINE KINASE INHIBITORS | ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO LTD (CN) | 2024-12-11 | — | — | EP | disclosed |
| EP-3615027-B1 | METHODS OF USE FOR TRISUBSTITUTED BENZOTRIAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS | AURIGENE DISCOVERY TECH LTD (IN) | 2021-07-14 | — | — | EP | disclosed |
| US-10793566-B2 | Bruton's tyrosine kinase inhibitors | ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO. LTD. (CN) | 2020-10-06 | — | — | US | disclosed |
| EP-3419960-B1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2020-07-01 | — | — | EP | disclosed |
| US-10662187-B2 | Bruton's tyrosine kinase inhibitors | ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO. LTD. (CN) | 2020-05-26 | — | — | US | disclosed |
| US-20190276453-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-09-12 | — | — | US | disclosed |
| US-20180170904-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-06-21 | — | — | US | disclosed |
| US-8569331-B2 | Substituted benzo[f]lmidazo[1,2-d]pyrido[2,3-b][1,4]diazepine compounds | ARQULE, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120267612-A1 | CROSS-LINKABLE COPPER PHTHALOCYANINE COMPLEXES | UNIVERSAL DISPLAY CORPORATION (US) | 2012-10-25 | — | — | US | disclosed |
| WO-2012061342-A2 | SUBSTITUTED BENZO-IMIDAZO-PYRIDO-DIAZEPINE COMPOUNDS | ARQULE, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| US-20120108574-A1 | Substituted Benzo-Imidazo-Pyrido-Diazepine Compounds | ARQULE, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| WO-2010082924-A1 | CROSS-LINKABLE COPPER PHTHALOCYANINE COMPLEXES | UNIVERSAL DISPLAY CORPORATION (US) | 2010-07-22 | — | — | WO | disclosed |
| US-20040266826-A1 | Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-30 | — | — | US | disclosed |
| EP-1423386-A1 | THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003022842-A1 | THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662187-B2 | Bruton's tyrosine kinase inhibitors | BTK, ABL1, SYK | MGLL 2799/4885CA2 3336/4885CA1 4768/4885 |
| US-20040266826-A1 | Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors | TNF, MMP9, MMP1 | MGLL 2688/4885CA2 561/4885CA1 612/4885 |
| US-20180170904-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | TYMP, TYMS, DUT | MGLL 2956/4885CA2 3653/4885CA1 4474/4885 |
| US-20120108574-A1 | Substituted Benzo-Imidazo-Pyrido-Diazepine Compounds | BRD4, BRPF3, BRD3 | MGLL 4857/4885CA2 3143/4885CA1 3854/4885 |
| US-10793566-B2 | Bruton's tyrosine kinase inhibitors | BTK, ABL1, SYK | MGLL 2799/4885CA2 3336/4885CA1 4768/4885 |
| US-20120267612-A1 | CROSS-LINKABLE COPPER PHTHALOCYANINE COMPLEXES | OCIAD1, OCIAD2, AOC2 | MGLL 3454/4885CA2 2868/4885CA1 2120/4885 |
| US-20190276453-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | MGLL 2799/4885CA2 3336/4885CA1 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.